EJEvardo Barros de Deus Nunes Junior

Evardo Barros de Deus Nunes Junior

*This is an algorithmically generated author record based on publicly available information.

Evardo Barros de Deus Nunes Junior has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oral Collagen Peptides and Skin Rejuvenation: A Systematic Review and an Updated Meta‐Analysis of Randomized Controlled Trials

    by Asia Batool, Muhammad Sharjeel Abbas, Ramzan Farooq, Makhzan Ali Akbar, Alisha Ahmed, Warisha Kanwal, Hamza Ali, Ashfaq Ahmad, Muhammad Junaid, Muhammad Suhaib Hanif, et al.

    Background: Cutaneous aging is characterized by progressive degradation of the extracellular matrix, manifesting as diminished hydration, loss of elasticity, and increased wrinkle depth. While oral hydrolyzed collagen peptides (HCPs) are increasingly utilized as systemic nutricosmetics, previous evidence syntheses have been limited by severe methodological heterogeneity and the inability to account for highly influential statistical outliers. This updated systematic review and meta‐analysis evaluated the clinical efficacy of oral collagen peptides for skin rejuvenation using an advanced statistical framework. Methods: A comprehensive literature search was conducted on PubMed (MEDLINE), Cochrane Library, and Google Scholar from inception to November 2025. Randomized controlled trials evaluating oral collagen supplementation in healthy adults were included. Data were synthesized using random effect models. To differentiate true clinical signals from statistical artifacts, analyses were reinforced with multilevel meta‐analysis, leave‐one‐out sensitivity testing, and dose–response spline regressions. Results: Thirty‐five randomized controlled trials comprising 2534 participants were included. Primary analysis revealed that oral collagen supplementation yielded statistically significant improvements in instrumental measures of skin hydration (SMD = 0.44; 95% CI: 0.15–0.73), skin elasticity (SMD = 0.62; 95% CI: 0.15–1.10), and barrier function via reduced transepidermal water loss (SMD = −0.39; 95% CI: −0.62 to −0.16). Efficacy appeared predominantly time‐dependent rather than dose‐dependent, with elasticity and barrier improvements requiring at least 12 weeks of supplementation. Conversely, rigorous sensitivity and multilevel analyses demonstrated that apparent improvements in structural parameters, specifically skin wrinkles, roughness, and dermal density, were statistical artifacts driven by high‐leverage outliers and severe inter‐study heterogeneity. Conclusion: Oral collagen peptide supplementation is an effective functional systemic moisturizer that produces significant time‐dependent improvements in cutaneous hydration, elasticity, and barrier retention. However, current evidence from trials of standard duration remains limited and inconsistent regarding structural anti‐aging effects, including macroscopic wrinkle reduction and dermal densification, and the existing data are simply not robust enough to support definitive conclusions in these domains.


  • Open Access

    Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Asia Batool, Muhammad Sharjeel Abbas, Saifullah Khan, Alisha Ahmad, Aiza Ahsan, Syeda Masooma Jafri, Makhzan Ali Akbar, Nabahat Shafi, Mrunalini Dandamudi, Prachi Gajjar C, et al.

    Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.